Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) has had fluctuating performances against competitors, with instances of both underperformance and outperformance. Recently, the DOJ filed a price reporting complaint, although Regeneron is ready to defend itself. Regeneron's Eylea sales performance was better than feared. Overpricing has potentially threatened its investor popularity. RBC Capital and Morgan Stanley have maintained their recommendations while Cantor Fitzgerald reasserted its neutral rating. A collaboration with Doudna-founded Mammoth on gene-editing therapies is initiated. The recent performance of REGN stock is believed to reflect the company's financial health. The stock is considered undervalued, offering potential investment opportunities to investors. There are concerns internally with insiders selling off $26m of stock. The Q1 earnings of REGN did not meet expectations due to a decrease in Eylea sales. There is anticipation on how Regeneron will perform in the upcoming year. Multiple financial analysts have made insight assessments, but the future looks promising as stock rallies and trades have remained strong.
Regeneron Pharmaceuticals REGN News Analytics from Wed, 01 Nov 2023 07:00:00 GMT to Fri, 10 May 2024 01:15:40 GMT -
Rating 5
- Innovation 8
- Information 7
- Rumor 2
